| Literature DB >> 25583578 |
Kristen R Crook1, Mengyao Jin1, Michael F Weeks1, Rishi R Rampersad1, Robert M Baldi1, Amy S Glekas1, Yajuan Shen1, Denise A Esserman1, Paul Little1, Todd A Schwartz1, Peng Liu2.
Abstract
MDSCs are a heterogeneous group of myeloid cells that suppress T cell activity in cancer and autoimmune disease. The effect of MDSCs on B cell function is not clear. Using the CIA model of autoimmune disease, we found an increase in M-MDSCs in the periphery of WT mice with CIA compared with naïve mice. These MDSCs were absent from the periphery of CCR2(-/-) mice that developed exacerbated disease. M-MDSCs, isolated from immunized mice, inhibited autologous CD4(+) T cell proliferation. The M-MDSC-mediated suppression of T cell proliferation was NO and IFN-γ dependent but IL-17 independent. Furthermore, we demonstrated for the first time that M-MDSCs from CIA mice also inhibited autologous B cell proliferation and antibody production. The suppression of B cells by M-MDSCs was dependent on the production of NO and PGE2 and required cell-cell contact. Administration of M-MDSCs rescued CCR2(-/-) mice from the exacerbated CIA phenotype and ameliorated disease in WT mice. Furthermore, adoptive transfer of M-MDSCs reduced autoantibody production by CCR2(-/-) and WT mice. In summary, M-MDSCs inhibit T cell and B cell function in CIA and may serve as a therapeutic approach in the treatment of autoimmune arthritis. © Society for Leukocyte Biology.Entities:
Keywords: autoimmune arthritis; chemokine receptor; collagen-induced arthritis; immunotherapy; rheumatoid arthritis
Mesh:
Substances:
Year: 2015 PMID: 25583578 PMCID: PMC4338846 DOI: 10.1189/jlb.4A0314-139R
Source DB: PubMed Journal: J Leukoc Biol ISSN: 0741-5400 Impact factor: 4.962